A new analysis from Texas Law Dog reveals the U.S. Department of Veterans Affairs (VA) has reduced benzodiazepine prescriptions for PTSD by 66% between 2020 and 2024, marking one of the largest shifts in veteran mental healthcare in decades.

The findings show a decisive move toward safer, evidence-based treatments — yet they also expose urgent challenges that remain. For example, over 14,000 veterans are still prescribed benzos annually, and women veterans are 67% more likely to receive them compared to men, despite clinical guidelines warning of heightened risk.

Key Findings:

  • VA reduced benzo prescriptions for PTSD from 21% of patients in 2020 to 7% in 2024
  • Women veterans face a 67% higher prescription rate than men
  • Long-term benzo use linked to a 3.1x greater risk of dependency and 2.2x higher aggression rates
  • 96% of VA PTSD programs now offer complementary therapies such as yoga, biofeedback, and meditation
  • SKY meditation trials show comparable results to gold-standard CPT therapy in reducing PTSD symptoms

Data Table – VA Benzodiazepine Use in PTSD Care (2020–2024):

Year% of PTSD Patients on BenzosWomen VeteransMen Veterans% of Programs Using CIH Therapies
202021%27%16%58%
202116%23%12%72%
202212%19%9%84%
20239%15%6%92%
20247%12%5%96%

Prescription Rates: This dramatic decline reflects a major policy success, showing that systemic change in prescribing behavior is possible when guidelines are backed by enforcement and education.

Gender Disparities: Women remain disproportionately prescribed benzos, pointing to an unresolved issue of gender bias in veteran mental healthcare.

Complementary Therapies: The near-universal adoption of CIH therapies signals a cultural shift within the VA toward non-pharmacologic treatment.

Veterans with PTSD face unique challenges, and the shift away from benzodiazepines represents both a healthcare milestone and an ongoing policy challenge. While the reduction improves safety and treatment outcomes, lingering gender disparities and residual prescribing patterns show that reform is incomplete. With veteran suicide rates still 57% higher than the general population, the VA’s evolving treatment model has direct implications for lives saved and long-term recovery outcomes.

Methodology:

  • Data Source: VA pharmacy records, PTSD treatment program reports (2020–2024)
  • Sample Size: Over 42,000 veterans nationwide
  • Segmentation: By gender, treatment type, and program adoption of complementary therapies
  • Statistical Confidence: 95% confidence interval (p < .01)

I invite you to explore the full study here.

TIME BUSINESS NEWS

JS Bin